AAV Quality Control Guide
AAV packaging quality control must go beyond vector titer to confirm that each production lot contains intact, functional, and sufficiently pure vector. A robust assessment combines genome integrity, full/empty/partial capsid distribution, residual DNA and protein, endotoxin, transduction activity, and stability testing to identify packaging or purification problems before use. Together, these orthogonal assays support reliable dose interpretation, lot consistency, and suitability for research or translational studies.
Direct Answer
qPCR or ddPCR may report a high vector genome concentration even when a batch contains many empty particles, incomplete genomes, aggregates, host-cell impurities, or microbial contaminants. Likewise, a numerically strong batch may show weak transduction if particle quality or biological activity is poor.
For this reason, viral vector analysis should connect orthogonal assays to a specific decision: whether a preparation is suitable for the planned experiment, animal study, or downstream development stage.
Release principle: define the quality attributes first, select complementary methods second, and set justified limits from platform history, assay capability, risk assessment, and intended use.
Genome titer does not independently quantify capsids that carry no genome or only a fragment.
A positive amplicon at one locus can coexist with truncation, rearrangement, deletion, or ITR damage elsewhere.
Host-cell proteins, residual DNA, process reagents, debris, and aggregates may affect interpretation, tolerability, or reproducibility.
An infectivity or potency assay is needed to relate physical quantity to functional output.
Core QC Panel
The table below translates each test into the question it answers and the way its result should be interpreted. Method choice may vary by serotype, genome design, matrix, sample concentration, and program maturity.
| Quality attribute | Question answered | Common methods | Acceptance considerations |
|---|---|---|---|
| 1. Vector titer | How many vector genomes or capsid particles are present? | qPCR, ddPCR, ELISA | Report the measurand and units clearly. A titer result should meet the dose and study-volume requirement, but it does not by itself establish infectivity or genome completeness. |
| 2. Purity | How much host- and process-related material remains? | SDS-PAGE, silver staining, HPLC; targeted HCP and residual-DNA assays as needed | Set impurity limits in relation to dose and use. Review the impurity pattern as well as total purity, especially for sensitive in vivo applications. |
| 3. Empty/full capsid ratio | What fraction of particles carries the intended payload? | AUC, TEM, SEC-MALS, orthogonal capsid-to-genome measurements | Lower empty-capsid burden generally improves dose efficiency. The target should reflect process capability, dose, indication, and immune-risk considerations. |
| 4. Genome integrity | Is the packaged sequence complete and structurally correct? | NGS, Southern blot, restriction analysis, multi-locus ddPCR | Confirm critical regions across the cassette, not only one short amplicon. Risk increases for constructs close to the AAV packaging capacity. |
| 5. Capsid integrity and aggregation | Are particles intact, monodisperse, and physically stable? | TEM, DLS, SEC-HPLC | Define limits for aggregation or degradation in the intended formulation and after relevant handling or storage conditions. |
| 6. Sterility / bioburden | Is viable microbial contamination absent or controlled? | Compendial sterility testing or a fit-for-stage bioburden method | The required assay and acceptance rule depend on material grade and study stage. Any unexpected growth requires investigation. |
| 7. Mycoplasma | Is the preparation free of mycoplasma contamination? | PCR/qPCR, culture-based methods | A negative result is expected for material entering cell-based or animal studies; assay suitability and inhibition controls should be documented. |
| 8. Endotoxin | Is pyrogenic bacterial endotoxin controlled? | LAL or another validated endotoxin assay | Use a dose- and route-based limit. The source article notes <5 EU/mL as a common benchmark in some research settings, but the correct specification may need to be stricter and should be justified for the application. |
Note: the examples above are planning guidance, not universal release specifications. Clinical or regulated programs require product-specific, phase-appropriate methods and predefined acceptance criteria.
Integrated Interpretation
Each assay closes a different evidence gap. Read the results as a connected control strategy rather than as isolated pass/fail numbers.
Supports dosing and yield calculations.
Interpret with capsid ratio and functional activity so genome copies are not mistaken for effective particles.
Separates useful vector from process impurities and nonproductive capsids.
Together these results explain why two lots with the same vg/mL may deliver different effective doses.
Confirms that payload and delivery shell remain structurally suitable.
Use orthogonal methods when a single assay cannot distinguish complete, truncated, partial, or aggregated species.
Connects contamination control with the intended biological effect.
This evidence becomes increasingly important as work moves from screening to in vivo and preclinical studies.
Risk-Based Planning
The same construct may need different evidence at different stages. The key is to increase analytical depth before uncertainty becomes costly or compromises an animal study.
| Use case | Minimum focus | Additional emphasis | Release approach |
|---|---|---|---|
| In vitro feasibility | Identity, titer, basic purity, mycoplasma | Functional transduction in the relevant cell system | Fit-for-experiment thresholds with transparent assay reporting |
| In vivo research | Full core panel, including endotoxin and microbial safety | Empty/full ratio, genome integrity, aggregation, and dose-relevant potency | Study- and route-specific limits informed by a documented safety assessment |
| Long-term or sensitive studies | Lot consistency and stability-indicating attributes | Orthogonal integrity testing, retained samples, and handling/stability checks | Predefined limits and comparability to representative lots |
| Preclinical / translational | Phase-appropriate identity, purity, potency, safety, and stability | Qualified or validated assays, method suitability, trend history, and deviations | Product-specific specifications justified by risk, dose, route, process, and regulatory strategy |
Troubleshooting
Discordant results are often informative. They can reveal which part of the product—not simply how much product—is limiting performance.
Check infectivity or potency, full-capsid content, capsid damage, aggregation, target-cell permissiveness, and assay normalization.
A clean protein profile cannot exclude truncated or rearranged genomes. Add multi-locus or sequence-level characterization.
Examine empty and partial particles. Total capsid concentration can overstate the amount of genome-containing vector.
Review formulation, freeze-thaw history, administration, tissue distribution, immune context, and whether the potency assay reflects the mechanism of action.
Release Workflow
A consistent review order makes gaps easier to see and prevents one favorable number from dominating the release decision.
Document dose, route, model, study duration, material grade, storage, and the consequence of failure.
Select critical quality attributes and justify alert or acceptance ranges before seeing the lot result.
Check sample concentration, matrix interference, controls, reportable range, precision, and method-specific uncertainty.
Compare quantity, composition, integrity, safety, and function; investigate discordance rather than averaging it away.
Record the data, deviations, rationale, limitations, reviewer, and final decision; trend results across lots where possible.
From Question to Evidence
Creative Biolabs can coordinate AAV production, titration, purity assessment, potency testing, and vector characterization in a unified quality-control strategy matched to the intended study.
Combine complementary measurements of quantity, capsid composition, genome integrity, and physical quality. This integrated profile helps identify why lots with similar genome titers may differ in effective dose or study performance.
Establish vector concentration with a clearly defined assay, measurand, and reporting unit. Titer data support dose calculations and yield assessment when interpreted alongside capsid composition and functional activity.
Assess host- and process-related impurities together with product-related heterogeneity. The resulting evidence helps determine whether residual material, empty particles, or aggregates could affect dosing, tolerability, or data interpretation.
Relate physical vector measurements to a relevant biological response. A fit-for-purpose potency or infectivity assay can reveal performance differences that are not explained by genome titer alone.
Coordinate vector packaging, purification, and quality review around the construct, serotype, dose, volume, and study stage. Consistent analytical checkpoints support lot comparison and more informed release decisions.
Selected Reading
Lock M, Alvira MR, Chen SJ, Wilson JM. Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Human Gene Therapy Methods. 2014;25(2):115–125. https://doi.org/10.1089/hgtb.2013.131.
McColl-Carboni A, Dollive S, Laughlin S, et al. Analytical characterization of full, intermediate, and empty AAV capsids. Gene Therapy. 2024;31(5–6):285–294. https://doi.org/10.1038/s41434-024-00444-2.
Tai PWL, Xie J, Fong K, et al. Adeno-associated virus genome population sequencing achieves full vector genome resolution and reveals human-vector chimeras. Molecular Therapy – Methods & Clinical Development. 2018;9:130–141. https://doi.org/10.1016/j.omtm.2018.02.002.
De BP, Chen A, Salami CO, et al. In vivo potency assay for adeno-associated virus–based gene therapy vectors using AAVrh.10 as an example. Human Gene Therapy Methods. 2018;29(3):146–155. https://doi.org/10.1089/hgtb.2017.246.
Frequently Asked Questions
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
